Internal Reference Number: FOI_9155
Date Request Received: 12/01/2026 00:00:00
Date Request Replied To: 21/01/2026 00:00:00
This response was sent via: By Email
Request Summary: Multiple Sclerosis
Request Category: Companies
| Question Number 1: How many patients who have a current diagnosis of Multiple Sclerosis received treatment in the last six months with any of the following treatment regimens (July 2025 鈥� December 2025)? 鈥� Ocrevus (ocrelizumab) IV (300mg/30ml) 鈥� Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) 鈥� Kesimpta (ofatumumab) 鈥� Briumvi (ublituximab) 鈥� Mavenclad (cladribine) 鈥� Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) 鈥� Natalizumab (Tysabri and Tyruko) 1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in January 2025 to June 2025 AND July 2025 鈥� December 2025?) 鈥� Ocrevus (ocrelizumab) IV (300mg/30ml) 鈥� Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) 鈥� Kesimpta (ofatumumab) 鈥� Briumvi (ublituximab) 鈥� Mavenclad (cladribine) 鈥� Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) 鈥� Natalizumab (Tysabri and Tyruko) | |
| Answer To Question 1: 0 results | |
| Question Number 2: How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (July 2025 鈥� December 2025)? 2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis? 鈥� Ocrevus (ocrelizumab) IV (300mg/30ml) 鈥� Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) 鈥� Kesimpta (ofatumumab) 鈥� Briumvi (ublituximab) 鈥� Mavenclad (cladribine) 鈥� Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) 鈥� Natalizumab (Tysabri and Tyruko) | |
| Answer To Question 2: 0 results | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 月色直播 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
